Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.3752W HIGH $14.26
Volume
177.37 K
Value Traded
18.49 M
Short % Float
5.48%
+0.56%Week
-1.72%1 Month
+17.69%3 Month
+24.68%6 Month
-80.95%5 Year
+1,902.42%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.57 B
EPS (TTM)
-0.26
P/E Ratio
-
Ent. Value
3.16 B
Total Shares
218.11 M
Float Shares
216.15 M
Insiders
0.99%
Institutions
109.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NEOG Catalyst Timeline
Dated clinical, regulatory and corporate events for Neogen Corporation
Past FDA Catalysts and PDUFA Decisions
How NEOG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Neogen Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NEOG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nassif MikhealDirector, Officer (CEO) | Buy | 505 1,579 held | $11.95 | 10/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NEOG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.3 % | 2.19 M | 143.50 K |
NEOG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NEOG ranks across every disease it competes in
Competitive Position is a premium feature
See how NEOG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNEOG News
NEOGNeogen Announces First-Quarter Earnings Release Date
Neogen Corporation has announced that it will release its first-quarter earnings on October 6, 2026, after market close. Following the release, executives will host a conference call and webcast to discuss the financial results. This event reflects the company's commitment to transparency and investor engagement.
Read more →NEOGNeogen® Committed to Helping Ranchers, Livestock Producers, and Horse Owners Fight Against New World Screwworm
Neogen® is focusing on supporting ranchers, livestock producers, and horse owners in their efforts to combat the New World Screwworm. The company aims to provide effective solutions to address this significant challenge in animal health. Their commitment highlights the importance of safeguarding livestock from this pest.
Read more →NEOGNeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
NeoGenomics has announced the pricing of an offering of $275 million in convertible senior notes. This financial move is part of the company's strategy to enhance its capital structure. Further details regarding the use of proceeds or the terms of the notes were not disclosed in the announcement.
Read more →NEOGNeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics has announced a proposed offering of $275 million in convertible senior notes. The details of the offering are currently limited, and further information may be provided in subsequent announcements. This financial move is part of the company's strategy to raise capital.
Read more →NEOGNeogen Reports Third Quarter Fiscal Year 2026 Financial Results
Neogen Corporation (NEOG) reported its financial results for the third quarter of fiscal year 2026, revealing a total revenue of $211.2 million, down 4.4% from the previous year. The company saw a 2.6% increase in Food Safety revenue, but Animal Safety revenues plummeted by 20.1% due to supplier issues. Neogen posted a net loss of $17.0 million and continues to maintain a positive outlook on its fiscal year 2026 revenue guidance despite operational challenges. Additionally, Neogen is set to transition its manufacturing for Petrifilm products and has announced a divestiture of its Genomics business.
Read more →NEOGNeogen to Release Third-Quarter Fiscal Year 2026 Financial Results on April 9, 2026
Neogen Corporation has announced the release date for its financial results for the third quarter of fiscal year 2026, which is set for April 9, 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the financial performance will be disclosed on that date.
Read more →NEOGNeogen Announces Sale of Genomics Business to Zoetis
Neogen Corporation has announced the sale of its global genomics business to Zoetis for $160 million as part of a strategy to streamline operations. The deal is expected to close by the end of the first half of the 2027 fiscal year, pending regulatory approval. Proceeds from the sale will primarily be used for debt reduction, allowing Neogen to focus on its core strengths in food and animal safety.
Read more →NEOGNeogen Issues Voluntary Nationwide Recall of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution
Neogen Corporation is recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination. Reports of adverse events in horses following intraarticular injections prompted this action. The recall includes both 2mL and 10mL vials, and Neogen is working with the FDA to address the issue. Customers are advised to discontinue use and quarantine the product.
Read more →NEOG▲ +31.6%on this news
Neogen Announces Second-Quarter 2026 Results
Neogen Corporation reported its second-quarter 2026 results, revealing a total revenue of $224.7 million, down 2.8% year-over-year. Despite this decline, core revenue rose by 2.9%, showcasing some growth amid challenges. The company recorded a net loss of $15.9 million but achieved an adjusted net income of $22.6 million. Moving forward, Neogen raised its guidance for fiscal year 2026, indicating optimism for future performance as it focuses on strategic transformations and improving operational efficiencies.
Read more →NEOGNeogen® Announces Two Senior Leadership Appointments
Neogen Corporation has announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer and Dr. Tammi Ranalli as Senior Vice President and General Manager of Global Food Safety. Both leaders bring significant experience from their previous roles and will be instrumental in driving Neogen's global strategy for innovation and growth in the Food Safety sector.
Read more →NEOG▲ +5.4%on this news
Neogen® To Participate in Upcoming Investor Conferences
Neogen Corporation will participate in two investor conferences in January 2026. The first is the CJS Securities 26th Annual New Ideas for the New Year conference, and the second is the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Mike Nassif will present at the latter event, highlighting Neogen's advancements in food safety and animal health.
Read more →NEOGNeogen Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer
Neogen Corporation announced the appointment of Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025. Riggsbee brings over 25 years of financial leadership experience from the diagnostics and healthcare sectors, previously serving at bioMérieux and Myriad Genetics. He will oversee Neogen's global finance organization and join the Executive Leadership Team. CEO Mike Nassif highlighted Riggsbee's track record in driving growth and operational excellence as key for the company’s future success.
Read more →NEOG▲ +16.5%on this news
Neogen Announces First-Quarter 2026 Results
Neogen Corporation reported its financial results for the first quarter of fiscal year 2026, noting a revenue of $209.2 million, which reflects a 3.6% decrease from the prior year. However, the company achieved a net income of $36.3 million, significantly improving from a net loss in the previous year, primarily due to a non-cash gain from divesting its Cleaners and Disinfectants business. The newly appointed CEO, Mike Nassif, highlighted opportunities for growth despite facing execution challenges and emphasized cost-restructuring measures. The company has reaffirmed its revenue outlook for the fiscal year 2026, predicting total revenues between $820 million and $840 million.
Read more →NEOGNeogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm
Neogen Corporation has announced a transition in its Board of Directors, with William Boehm retiring effective October 23, 2025, after serving since 2011. His contributions have been acknowledged as vital for the company’s strategic direction. Avi Pelossof will join the board on October 24, 2025, bringing extensive experience from his leadership roles at Immucor Inc. and Alere Inc. The transition aims to further drive innovation and growth at Neogen.
Read more →NEOG▼ -10.9%on this news
Neogen Announces Fourth-Quarter 2025 Results
Neogen Corporation reported its fourth-quarter 2025 results, revealing a revenue of $225.5 million but a significant net loss of $612.2 million due to a non-cash goodwill impairment. The company highlighted ongoing challenges with softer market conditions and inflation impacting food production, though it noted slight growth in its Food Safety core revenue. Looking ahead, Neogen projects continued end-market weakness but aims for revenue between $820 million and $840 million in fiscal year 2026, alongside expected adjusted EBITDA improvements. The company remains committed to addressing operational challenges and believes in its potential for future growth in the food safety sector.
Read more →NEOG▼ -17.3%on this news
William Blair Growth Stock Conference
Neogen recently presented at the William Blair Growth Stock Conference, outlining its ongoing integration of the former 3M Food Safety division. The company is focused on enhancing its food safety and animal safety product offerings amid significant market challenges. While it has made notable progress in this transformational journey, the integration has encountered unforeseen difficulties. Additionally, Neogen anticipates soft market conditions affecting its gross margins. The company remains committed to accelerating growth in its Food Safety segment amidst the uncertainties in global trade.
Read more →NEOGNeogen Announces Board Transition with Appointment of Andrea Wainer and Retirement of James P. Tobin
Neogen Corporation announced a transition on its Board of Directors, with James P. Tobin retiring effective May 31, 2025, after nine years of service. Andrea Wainer has been appointed to the board starting June 1, 2025, bringing over 25 years of experience in the diagnostics and healthcare sector. Neogen's Board Chair, James C. Borel, expressed gratitude for Tobin's leadership and highlighted the strategic value of Wainer's expertise as the company advances in food safety solutions.
Read more →NEOGPetrifilm at Neogen
Neogen is actively progressing with the consolidation of its Petrifilm manufacturing operations in Lansing, MI, aimed at enhancing productivity and sustainability. The company has started installation of modern equipment and expects test production to begin in fall 2025. However, various risks, including successful implementation of a new CEO succession plan and the impact of global disruptions, complicate the forward-looking statements made by Neogen. Key management positions are being filled from within the industry, particularly utilizing expertise from former 3M employees.
Read more →NEOG▼ -28.7%on this news
Neogen Announces CEO Transition Board has Formed Search Committee and Engaged Leading Executive Search Firm
Neogen Corporation announced a leadership transition as CEO John Adent steps down after an eight-year tenure. The Board of Directors has formed a search committee, including Board Chair Jim Borel, to find a successor while Adent continues to lead during the transition. The Board expressed confidence in Neogen’s strategic initiatives and the company’s growth potential in the food safety market. Adent praised his team and highlighted the importance of their solutions and innovation capabilities in advancing food security.
Read more →NEOG▼ -28.7%on this news
Neogen Announces Third-Quarter 2025 Results
Neogen Corporation announced its financial results for the third quarter of 2025, reporting revenues of $221.0 million, down 3.4% from the previous year, and a net loss of $11.0 million. Despite a solid 7% growth in core revenue within the Food Safety segment, the company faced challenges including a decline in sample collection revenue. Neogen's management cited macroeconomic uncertainties and declining consumer confidence as significant factors affecting performance, leading to an updated full-year guidance. The company remains optimistic about future growth opportunities as it continues to progress in its strategic initiatives, including production line advancements.
Read more →About Neogen Corporation
Headquarters620 LESHER PLACE, LANSING, MI, 48912
BIOPHARMAWATCH ELITE PLUS
Trade the next NEOG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime